The Journal of Practical Medicine ›› 2023, Vol. 39 ›› Issue (6): 655-659.doi: 10.3969/j.issn.1006⁃5725.2023.06.001

• Clinical Advances •     Next Articles

Research progress of combined immunotherapy for metastatic pancreas cancer 

ZHANG Xijie*,LI Xin, ZHOU Wence.   

  1. The Second School of Clinical Medicine,Lanzhou University,Lanzhou 730000,China

  • Online:2023-03-25 Published:2023-03-25
  • Contact: ZHOU Wence E⁃mail:zhouwc129@163.com

Abstract:

Pancreatic cancer is a highly malignant tumor of the digestive system,especially metastatic pancreatic cancer is characterized by short course of disease,rapid progression and high mortality. Although gem⁃ citabine has become the standard treatment for advanced pancreatic cancer,the therapeutic effect still falls short of the expected survival. Therefore,a variety of treatments such as radiotherapy and chemotherapy,immunotherapy, targeted therapy and nanotechnology have been gradually developed in clinic,however,the effect of single drug therapy for metastatic pancreatic cancer is not satisfactory at present. Researchers are considering the combination therapy to explore new treatment schemes,and there are many clinical and basic studies of combined immunotherapy for metastatic pancreatic cancer. However,the treatment in this field is still controversial. This article reviews the research progress of combined immunotherapy for metastatic pancreatic cancer in recent years.

Key words:

metastatic pancreas cancer, immunotherapy, combined therapy